Ribozyme and omics

Anti-cancer development based on RNA platform technology Core competence to meet diverse unmet medical needs Molecular Genetics Lab


Rznomics Inc. has the core competencies to meet a variety of unmet medical needs through the development of anticancer biopharmaceuticals based on RNA platform technology. Based on innovative RNA-based biopharmaceuticals, Rznomics aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases.

Advantages of technology